Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $56.5 million.

  • Iradimed's Cash & Current Investments rose 929.04% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 929.04%. This contributed to the annual value of $52.2 million for FY2024, which is 496.7% up from last year.
  • Iradimed's Cash & Current Investments amounted to $56.5 million in Q3 2025, which was up 929.04% from $53.0 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Cash & Current Investments ranged from a high of $62.5 million in Q4 2021 and a low of $42.8 million during Q1 2023
  • Its 5-year average for Cash & Current Investments is $52.1 million, with a median of $52.2 million in 2022.
  • In the last 5 years, Iradimed's Cash & Current Investments surged by 2024.57% in 2021 and then crashed by 1603.53% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Cash & Current Investments stood at $62.5 million in 2021, then decreased by 7.26% to $58.0 million in 2022, then fell by 14.15% to $49.8 million in 2023, then grew by 4.97% to $52.2 million in 2024, then increased by 8.22% to $56.5 million in 2025.
  • Its Cash & Current Investments was $56.5 million in Q3 2025, compared to $53.0 million in Q2 2025 and $50.3 million in Q1 2025.